Michał Krupa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Michał Krupa has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Iga Wiak
Faculty of Medicine, Medical University of Warsaw, 61 Żwirki i Wigury St., 02-091 Warsaw, Poland
1 shared publication - Joachim Pachucki
Faculty of Medicine, Medical University of Warsaw, 61 Żwirki i Wigury St., 02-091 Warsaw, Poland
1 shared publication - Maria Maślińska
Department of Rheumatology, National Institute of Geriatrics, Rheumatology, and Rehabilitation, Warsaw, Poland
1 shared publication - Martyna Dziewit
Department of Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland
1 shared publication - Marzena Olesińska
Department of Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland
1 shared publication - Paweł Kasprzak
Department of Orthopedics and Traumatology, Medical University of Warsaw, 4 W. H. Lindleya St., 02-005 Warsaw, Poland
1 shared publication
Latest Publications
- 18 July 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (8) , 215
Favorable clinical outcomes of biologic and targeted therapies in refractory eosinophilic fasciitis: a case-based systematic review
Eosinophilic fasciitis (EF) is a rare autoimmune disease characterized by fascial inflammation, skin induration, eosinophilia, and progressive functional impairment. Although glucocorticosteroids (GCs) remain the first-line therapy, some patients develop refractory or steroid-dependent disease, highlighting the need for alternative treatment strategies. This case-based review summarizes current evidence on biologic and targeted therapies in severe EF and presents a case of successful treatment with tocilizumab (TCZ). A systematic review of PubMed, Scopus, and Web of Science databases identified 35 eligible articles published between 2008 and 2026. Qualitative synthesis included 49 patients treated with biologic or targeted agents, most commonly rituximab (n = 14), tocilizumab (n = 9), infliximab (n = 7), and mepolizumab (n = 5). Partial or complete response was achieved in 47 of 49 (96%) patients across all treatment groups. Biologic therapy was associated with a pronounced steroid-sparing effect, enabling GCs dose reduction or complete withdrawal in the majority of refractory patients. Furthermore, we describe a 28-year-old man with progressive, treatment-resistant EF who failed to respond adequately to GCs and methotrexate. Following initiation of weekly subcutaneous TCZ, the patient showed marked clinical, laboratory, and radiological improvement, with normalization of inflammatory markers, regression of fascial edema on MRI, and substantial functional recovery. Available case-based evidence suggests that biologic and targeted therapies, including IL-6 inhibition, may be promising options in selected patients with severe, refractory, or GC-dependent EF. However, considering the high risk of publication bias and reliance on case reports, prospective multicenter studies are required to establish standardized treatment recommendations.
- 18 July 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (8) , 215
Favorable clinical outcomes of biologic and targeted therapies in refractory eosinophilic fasciitis: a case-based systematic review
Eosinophilic fasciitis (EF) is a rare autoimmune disease characterized by fascial inflammation, skin induration, eosinophilia, and progressive functional impairment. Although glucocorticosteroids (GCs) remain the first-line therapy, some patients develop refractory or steroid-dependent disease, highlighting the need for alternative treatment strategies. This case-based review summarizes current evidence on biologic and targeted therapies in severe EF and presents a case of successful treatment with tocilizumab (TCZ). A systematic review of PubMed, Scopus, and Web of Science databases identified 35 eligible articles published between 2008 and 2026. Qualitative synthesis included 49 patients treated with biologic or targeted agents, most commonly rituximab (n = 14), tocilizumab (n = 9), infliximab (n = 7), and mepolizumab (n = 5). Partial or complete response was achieved in 47 of 49 (96%) patients across all treatment groups. Biologic therapy was associated with a pronounced steroid-sparing effect, enabling GCs dose reduction or complete withdrawal in the majority of refractory patients. Furthermore, we describe a 28-year-old man with progressive, treatment-resistant EF who failed to respond adequately to GCs and methotrexate. Following initiation of weekly subcutaneous TCZ, the patient showed marked clinical, laboratory, and radiological improvement, with normalization of inflammatory markers, regression of fascial edema on MRI, and substantial functional recovery. Available case-based evidence suggests that biologic and targeted therapies, including IL-6 inhibition, may be promising options in selected patients with severe, refractory, or GC-dependent EF. However, considering the high risk of publication bias and reliance on case reports, prospective multicenter studies are required to establish standardized treatment recommendations.
- Open Access
- 10 April 2026
- Published by MDPI AG in Prosthesis
- Vol. 8 (4) , 38
Patellar Maltracking in Total Knee Arthroplasty: Mechanisms, Prevention and Treatment
Patellar maltracking is among the most common causes of anterior knee pain after total knee arthroplasty (TKA), underscoring the need for accurate prevention and treatment. Therefore, the purpose of this narrative review is to provide a comprehensive overview of current evidence on post-TKA tracking, focusing on component alignment, preoperative patient assessment, and revision treatment options. A PubMed database search was performed, leveraging the literature from the last 20 years, and the results were qualitatively synthesized. According to current studies, several precautions should be taken to prevent patellofemoral stress and, consequently, patellar maltracking, such as avoiding internal rotation, valgus alignment, and excessive flexion of the femoral component and internal rotation of the tibial component. Regarding alignment strategies, kinematic alignment appears to offer potential benefits over mechanical alignment in certain functional outcomes and patient satisfaction scores. However, these differences should be interpreted cautiously as they may not always exceed the minimal clinically important difference. Furthermore, recent evidence indicates that quadriceps biomechanics influence TKA outcomes, potentially suggesting that conventional surgical approaches may need to be individualized, though these preliminary findings require prospective validation. Currently, robotic-assisted surgery represents a developmental direction for patient-tailored interventions and offers great promise for better prosthesis customization to the individual patient. Integration of imaging data with dynamic soft-tissue assessment enables more predictable reconstruction of joint kinematics. Regarding surgical treatment, the selection of specific methods requires a prior clinical and radiographic assessment. Indications range from patellar maltracking direction and component malrotation to patient preferences and rehabilitation potential. Ultimately, the future of TKA relies on personalized interventions to prevent complications and improve patient outcomes. This evolution is driven by the shift from mechanical alignment to kinematic alignment, alongside quadriceps tendon assessment and intraoperative robotic-assisted measurement, all aimed at optimizing the accuracy of implant positioning.
- 10 April 2026
- Published by MDPI AG in Prosthesis
- Vol. 8 (4) , 38
Open AccessPatellar Maltracking in Total Knee Arthroplasty: Mechanisms, Prevention and Treatment
Patellar maltracking is among the most common causes of anterior knee pain after total knee arthroplasty (TKA), underscoring the need for accurate prevention and treatment. Therefore, the purpose of this narrative review is to provide a comprehensive overview of current evidence on post-TKA tracking, focusing on component alignment, preoperative patient assessment, and revision treatment options. A PubMed database search was performed, leveraging the literature from the last 20 years, and the results were qualitatively synthesized. According to current studies, several precautions should be taken to prevent patellofemoral stress and, consequently, patellar maltracking, such as avoiding internal rotation, valgus alignment, and excessive flexion of the femoral component and internal rotation of the tibial component. Regarding alignment strategies, kinematic alignment appears to offer potential benefits over mechanical alignment in certain functional outcomes and patient satisfaction scores. However, these differences should be interpreted cautiously as they may not always exceed the minimal clinically important difference. Furthermore, recent evidence indicates that quadriceps biomechanics influence TKA outcomes, potentially suggesting that conventional surgical approaches may need to be individualized, though these preliminary findings require prospective validation. Currently, robotic-assisted surgery represents a developmental direction for patient-tailored interventions and offers great promise for better prosthesis customization to the individual patient. Integration of imaging data with dynamic soft-tissue assessment enables more predictable reconstruction of joint kinematics. Regarding surgical treatment, the selection of specific methods requires a prior clinical and radiographic assessment. Indications range from patellar maltracking direction and component malrotation to patient preferences and rehabilitation potential. Ultimately, the future of TKA relies on personalized interventions to prevent complications and improve patient outcomes. This evolution is driven by the shift from mechanical alignment to kinematic alignment, alongside quadriceps tendon assessment and intraoperative robotic-assisted measurement, all aimed at optimizing the accuracy of implant positioning.